News

Our Fall Clinical Forum highlights Brenzavvy (bexagliflozin), a lower-cost option for type 2 diabetes, and shares clinical recommendations for newly approved therapies.

We’re committed to offering timely, clinically relevant information about newly approved medications. These updates are designed to assist with the development of criteria for clinical review, prior authorization, or utilization management strategies.

The 340B Coalition Summer Conference is right around the corner, kicking off on July 21, and we are eager to attend several sessions!

Biologic medications and their biosimilar counterparts are transforming how we treat complex health conditions. Understanding the differences between the two can help patients and providers make informed decisions about treatment options. Today, we take a closer look at the evolving biosimilar market, share updates regarding Humira and its biosimilar counterparts, and introduce emerging biosimilar products for Stelara.

April 16 marks the anniversary of PDMI's incorporation date. With that milestone in mind, we wanted to share a few of the major moments that have helped shape the company we are today.